Effective Late Stage Pathways For Biosimilar Products

February 16, 2018

In this presentation, ‘Effective Late Stage Pathways for Biosimilar Products’,  Dr. JingPing Yeo, outlines strategies to enhance operational efficiencies, optimize patient recruitment and retention and leverage data driven monitoring for data surveillance in Biosimilar studies.

Learn about ‘Effective Late Stage Pathways for Biosimilar Products’, in this presentation by PAREXEL’s  Dr. JingPing Yeo. Dr. Yeo outlines strategies to enhance operational efficiencies, optimize patient recruitment and retention and leverage data driven monitoring for data surveillance in Biosimilar studies.

View Presentation Here >

Previous Article
Three Ways to Mitigate the Risk of Late-stage Failure in CNS Drug Development
Three Ways to Mitigate the Risk of Late-stage Failure in CNS Drug Development

Read this presentation to find out more!

Next Flipbook
Clinical Outcome Assessments Can Help Persuade Payers, If You Select (Or Develop) Them Wisely
Clinical Outcome Assessments Can Help Persuade Payers, If You Select (Or Develop) Them Wisely

Learn about how Clinical Outcome Assessments can help persuade payers!

×

Speak to one of our experts today

First Name
Last Name
Company Name
Title
Country
Tell us how we can help
We'll be in touch shortly!
Error - something went wrong!
×

Register now for full access to all the content

First Name
Last Name
Company Name
Title
Country
Thank you for registering!
Error - something went wrong!